Developing Next-Generation Natural Killer Cell Immunotherapies Targeting Oncofetal Receptors in Solid Cancers (2026-2027)

Triple-negative breast cancer (TNBC) is one of the most aggressive forms of breast cancer, with limited treatment options and high relapse rates. Many TNBC tumours, as well as some ovarian and lung cancers, display a protein called ROR1, which is rarely found in healthy adult tissues. This makes ROR1 an ideal target for new cancer therapies. Researchers at The University of Queensland (UQ) have developed a unique antibody, A9, that binds a specific part of ROR1 not targeted by existing drugs, reducing the risk of side effects. In laboratory studies, A9 has shown superior tumour cell binding and cancer-killing activity compared to the current best ROR1 antibody. This project will combine the A9 antibody with Cartherics¿TM) Australian-made stem cell platform to create ¿off-the-shelf¿ natural killer (NK) immune cells. These ROR1-targeted NK cells will be made in a Good Manufacturing Practice (GMP) facility, enabling consistent, large-scale production ready for clinical testing. If success